GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bellerophon Therapeutics Inc (OTCPK:BLPH) » Definitions » FCF Yield %

Bellerophon Therapeutics (Bellerophon Therapeutics) FCF Yield % : -1,830.71 (As of Apr. 30, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Bellerophon Therapeutics FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Bellerophon Therapeutics's Trailing 12-Month Free Cash Flow is $-12.34 Mil, and Market Cap is $0.67 Mil. Therefore, Bellerophon Therapeutics's FCF Yield % for today is -1,830.71%.

The historical rank and industry rank for Bellerophon Therapeutics's FCF Yield % or its related term are showing as below:

BLPH' s FCF Yield % Range Over the Past 10 Years
Min: -3079.89   Med: -984.06   Max: -8.38
Current: -1830.71


During the past 11 years, the highest FCF Yield % of Bellerophon Therapeutics was -8.38%. The lowest was -3079.89%. And the median was -984.06%.

BLPH's FCF Yield % is ranked worse than
98.32% of 1551 companies
in the Biotechnology industry
Industry Median: -15.06 vs BLPH: -1830.71

Bellerophon Therapeutics's FCF Margin % for the quarter that ended in Sep. 2023 was 0.00%.


Bellerophon Therapeutics FCF Yield % Historical Data

The historical data trend for Bellerophon Therapeutics's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bellerophon Therapeutics FCF Yield % Chart

Bellerophon Therapeutics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
FCF Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -32.95 -53.80 -31.41 -77.12 -204.70

Bellerophon Therapeutics Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
FCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -192.61 -200.53 15.85 -233.21 -520.76

Competitive Comparison of Bellerophon Therapeutics's FCF Yield %

For the Biotechnology subindustry, Bellerophon Therapeutics's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bellerophon Therapeutics's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bellerophon Therapeutics's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Bellerophon Therapeutics's FCF Yield % falls into.



Bellerophon Therapeutics FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Bellerophon Therapeutics's FCF Yield % for the fiscal year that ended in Dec. 2022 is calculated as

FCF Yield %=Free Cash Flow / Market Cap
=-17.77 / 8.681139
=-204.70%

Bellerophon Therapeutics's annualized FCF Yield % for the quarter that ended in Sep. 2023 is calculated as

FCF Yield %=Free Cash Flow * Annualized Factor / Market Cap
=-6.332 * 4 / 4.86368176
=-520.76%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bellerophon Therapeutics FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.


Bellerophon Therapeutics FCF Yield % Related Terms

Thank you for viewing the detailed overview of Bellerophon Therapeutics's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Bellerophon Therapeutics (Bellerophon Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
184 Liberty Corner Road, Suite 302, Warren, NJ, USA, 07059
Bellerophon Therapeutics Inc is a clinical-stage therapeutics company. The firm develops innovative products combining novel drugs and devices to treat cardiopulmonary diseases. It develops products under its INOpulse platform, which is an extension of the technology that is used in hospitals to deliver continuous-flow inhaled nitric oxide. The company's products are aimed at the treatment of different kinds of pulmonary hypertension.
Executives
Puissance Life Science Opportunities Fund Vi 10 percent owner 950 THIRD AVENUE, FL 25, NEW YORK NY 10022
Naseem Amin director 53 FRONTAGE ROAD, SUITE 301, HAMPTON NJ 08827
Mary Ann Cloyd director 184 LIBERTY CORNER ROAD, SUITE 302, WARREN NJ 07059
Theodore T Wang director C/O PUISSANCE CAPITAL MANAGEMENT LP, 950 THIRD AVENUE, 25TH FLOOR, NEW YORK NY 10022
Scott P Bruder director C/O BELLEROPHON THERAPEUTICS, 53 FRONTAGE ROAD, SUITE 301, HAMPTON NJ 08827
Crispin Teufel director 184 LIBERTY CORNER ROAD, SUITE 302, WARREN NJ 07059
Puissance Capital Fund (gp) Llc 10 percent owner 950 THIRD AVENUE, 25TH FLOOR, NEW YORK NY 10022
Parag Suresh Shah officer: VP of Business Operations C/O BELLEROPHON THERAPEUTICS, INC., 184 LIBERTY CORNER ROAD, SUITE 302, NEW JERSEY NJ 07059
Martin Dekker officer: See Remarks 53 FRONTAGE ROAD, SUITE 301, PERRYVILLE III CORPORATE PARK, HAMPTON NJ 08827
Peter Fernandes officer: See Remarks PERRYVILLE III CORPORATE PARK, 53 FRONTAGE ROAD, SUITE 301, HAMPTON NJ 08827
Bobae Kim officer: VP Reg. Affairs & Quality 184 LIBERTY CORNER ROAD, SUITE 302, WARREN NJ 07059
Nicholas Laccona officer: Controller, (PFO & PAO) 184 LIBERTY CORNER ROAD, SUITE 302, WARREN NJ 07059
Steven B Klinsky 10 percent owner C/O NEW MOUNTAIN CAPITAL, L.L.C., 1633 BROADWAY, 48TH FLOOR, NEW YORK NY 10019
New Mountain Capital, L.l.c. 10 percent owner 1633 BROADWAY, 48TH FLOOR, NEW YORK NY 10019
New Mountain Investments Ii, Llc 10 percent owner 787 SEVENTH AVENUE, 49TH FLOOR, NEW YORK NY 10019

Bellerophon Therapeutics (Bellerophon Therapeutics) Headlines

From GuruFocus

Bellerophon to Present at the H.C. Wainwright BioConnect 2022 Conference

By GuruFocusNews GuruFocusNews 01-10-2022